Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Aug 26, 2014; 6(8): 744-754
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.744
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.744
Peroxisome proliferator-activated receptors for hypertension
Daisuke Usuda, Tsugiyasu Kanda, Department of Community Medicine, Kanazawa Medical University Himi Municipal Hospital, Himi-shi 935-8531, Toyama-ken, Japan
Author contributions: Usuda D and Kanda T designed and wrote the introductory editorial for the paper.
Correspondence to: Daisuke Usuda, MD, MTM, Department of Community Medicine, Kanazawa Medical University Himi Municipal Hospital, 1130 Kurakawa, Himi-shi 935-8531, Toyama-ken, Japan. united19771108@yahoo.co.jp
Telephone: +81-766-741900 Fax: +81-766-741901
Received: December 26, 2013
Revised: June 6, 2014
Accepted: June 27, 2014
Published online: August 26, 2014
Processing time: 264 Days and 21 Hours
Revised: June 6, 2014
Accepted: June 27, 2014
Published online: August 26, 2014
Processing time: 264 Days and 21 Hours
Core Tip
Core tip: Lifestyle-related diseases are major public health problem worldwide, and the prevalence of these diseases and subsequent complications has increased rapidly over the past 20 years. It has been a decade or more since the first report of the pleiotropic effects of peroxisome proliferator-activated receptors (PPARs), and numerous studies on their novel effects continue to appear every month. In addition to their effects on blood pressure, atherosclerosis, and kidney dysfunction, anti-cancer effects of PPARγ ligands have been reported recently. The effectiveness of PPAR agonists in the treatment of lifestyle-related diseases will be increasingly appreciated. This review summarizes the current literature on PPARs.